RT Journal Article
SR Electronic
T1 674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A764
OP A764
DO 10.1136/jitc-2023-SITC2023.0674
VO 11
IS Suppl 1
A1 Chung, Christine H
A1 Adkins, Douglas
A1 Dimitrios Colevas, A
A1 Rodriguez, Cristina
A1 Park, Jong Chul
A1 Gibson, Michael K
A1 Sukari, Ammar
A1 Burtness, Barbara
A1 Johnson, Faye
A1 Julian, Ricklie
A1 Saba, Nabil F
A1 Worden, Francis
A1 Dunn, Lara A
A1 Seiwert, Tanguy Y
A1 Jotte, Robert M
A1 Haddad, Rami
A1 Gabrail, Nashat
A1 Bauman, Julie E
A1 Chaney, Marya
A1 Agensky, Laura
A1 Goel, Apollina
A1 Quayle, Steve
A1 Margossian, Steven
A1 Levisetti, Matteo
A1 Pai, Sara
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A764.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.